Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Citi
Mallinckrodt
Novartis
QuintilesIMS
Cerilliant
Harvard Business School
Chubb
Farmers Insurance
Chinese Patent Office

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,703,780

« Back to Dashboard

Summary for Patent: 8,703,780
Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/526,161
Patent Claim Types:
see list of patent claims
Use; Device; Delivery;

Drugs Protected by US Patent 8,703,780

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ➤ Sign Up
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,703,780

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,809,273 Inhibitors of Bruton's tyrosine kinase ➤ Sign Up
8,552,010 Inhibitors of Bruton'S tyrosine kinase ➤ Sign Up
8,697,711 Inhibitors of bruton'S tyrosine kinase ➤ Sign Up
7,514,444 Inhibitors of bruton's tyrosine kinase ➤ Sign Up
9,139,591 Inhibitors of bruton's tyrosine kinase ➤ Sign Up
7,960,396 Inhibitors of Bruton's tyrosine kinase ➤ Sign Up
8,236,812 Inhibitors of bruton's tyrosine kinase ➤ Sign Up
8,748,438 Inhibitors of Bruton's tyrosine kinase ➤ Sign Up
9,133,198 Inhibitors of bruton'S tyrosine kinase ➤ Sign Up
8,735,403 Inhibitors of Bruton's tyrosine kinase ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,703,780

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 531263 ➤ Sign Up
Australia 2006348662 ➤ Sign Up
Australia 2008232762 ➤ Sign Up
Australia 2010201052 ➤ Sign Up
Australia 2012205166 ➤ Sign Up
Brazil PI0622054 ➤ Sign Up
Brazil PI0622277 ➤ Sign Up
Brazil PI0810086 ➤ Sign Up
Canada 2663116 ➤ Sign Up
Canada 2681756 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Boehringer Ingelheim
QuintilesIMS
McKinsey
UBS
Accenture
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot